Raredr

Top Medical News Today

Positive Initial Data Announced for Setmelanotide as Rare Obesity Treatment
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
Triple Threat: HD Patient Researches, Educates and Advocates
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Rumbaugh Awarded $2-Million NIHMH Funded Grant for Syngap1 Therapeutic Development
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Ron Cooper Talks A4250, Inception of Albireo Pharma and the Importance of Orphan Drugs
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
FDA Commissioner Releases Statement on the Importance of the Drug Quality and Security Act
FDA Commissioner Scott Gottlieb, MD, released a statement regarding the importance of the Drug Quality and Security Act, as well as compounded drug safety.
Data Presented at ICPP Show Encouraging Results for Givosiran in AHP Patients
Alnylam Pharmaceuticals is presenting new data on Givosiran (ALN-AS1) for the treatment of acute hepatic porphyrias (AHP).
NBA Superstar Joins the Be the Match Team
Memphis Grizzlies point guard Mike Conley announced his new team last week: the organization that operates the world’s top donor registry, Be the Match.
How to Manage an NTM Infection
Most people do not become ill from Nontuberculous mycobacteria (NTM), but in people of compromised health, an infection can lead to more serious problems.
New Data Provide Beneficial Evidence of Soliris (eculizumab) in PNH Patients
At the 22nd Congress of the EHA in Madrid, Alexion presented new data that displayed benefits of Soliris (eculizumab) treatment for patients with PNH.
New Data Show Survival Improvement with Adcetris in Hodgkin Lymphoma Patients
New data shows promising results from the Phase 3 ECHELON-1 Clinical Trial that evaluated Adcetris (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
RareDR Resource Guide
$vacMongoViewPlus$ $vAR$